Literature DB >> 8394295

Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712.

W H Harvey1, T R Fleming, P J Goodman, J H Harvey, S E Rivkin, J S MacDonald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8394295     DOI： 10.1007/bf00873909

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  4 in total

1.  2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo.

Authors:  J R Bertino; W L Sawicki; B A Moroson; A R Cashmore; E F Elslager
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

2.  Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro.

Authors:  B A Kamen; B Eibl; A Cashmore; J Bertino
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

3.  Pharmacokinetics of trimetrexate (NSC 352122) in monkeys.

Authors:  F M Balis; C M Lester; D G Poplack
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

Authors:  H Diddens; D Niethammer; R C Jackson
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701
  4 in total
  1 in total

1.  Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).

Authors:  F L Meyskens; J Jacobson; B Nguyen; G R Weiss; D R Gandara; J S MacDonald
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.